Revolution Medicines Inc (FRA:42Z)

€ 55 -1.5 (-2.65%) Market Cap: 9.33 Bil Enterprise Value: 7.95 Bil PE Ratio: 0 PB Ratio: 6.27 GF Score: 42/100

Q3 2024 Revolution Medicines Inc Earnings Call Transcript
Nov 06, 2024

€53 (+3.92%)

Earnings
Q2 2024 Revolution Medicines Inc Earnings Call Transcript
Aug 07, 2024

€39.4 (+2.07%)

Earnings
Q1 2024 Revolution Medicines Inc Earnings Call Transcript
May 08, 2024

€36

Earnings
Q4 2023 Revolution Medicines Inc Earnings Call Transcript
Feb 26, 2024

€27.4 (+2.24%)

Earnings
Revolution Medicines Inc at JPMorgan Healthcare Conference Transcript
Jan 09, 2024
Q3 2023 Revolution Medicines Inc Earnings Call Transcript
Nov 06, 2023

€20.6 (+4.57%)

Earnings
Revolution Medicines Inc To Discuss ESMO Data Presentation Call Transcript
Oct 22, 2023
Q2 2023 Revolution Medicines Inc Earnings Call Transcript
Aug 08, 2023

€26.8 (-4.96%)

Earnings
Revolution Medicines Inc To Acquire EQRx Inc Call Transcript
Aug 01, 2023
Revolution Medicines Inc at Barclays Lunchtime Biotech Fireside Chat Series Transcript
Jun 15, 2023
Revolution Medicines Inc at Goldman Sachs Healthcare Conference Transcript
Jun 14, 2023
Q1 2023 Revolution Medicines Inc Earnings Call Transcript
May 08, 2023

€22 (+0.92%)

Earnings
Revolution Medicines Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 20, 2023
Q4 2022 Revolution Medicines Inc Earnings Call Transcript
Feb 27, 2023

€22.8

Earnings
Revolution Medicines Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2023
Revolution Medicines Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
Dec 01, 2022
Revolution Medicines Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 12, 2022
Q2 2022 Revolution Medicines Inc Earnings Call Transcript
Aug 09, 2022

€23.8 (-4.03%)

Earnings
Revolution Medicines Inc Annual Shareholders Meeting Transcript
Jun 16, 2022
Revolution Medicines Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript
Feb 10, 2022
Q2 2021 Revolution Medicines Inc Earnings Call Transcript
Aug 11, 2021

€23 (-1.71%)

Earnings
Revolution Medicines Inc at H C Wainwright Global Life Sciences Conference (Virtual) Transcript
Mar 09, 2021
Revolution Medicines Inc at Cowen Healthcare Conference (Virtual) Transcript
Mar 03, 2021
Revolution Medicines Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 12, 2021

Q2 2023 Revolution Medicines Inc Earnings Call Transcript

Aug 08, 2023 / 08:30PM GMT

Release Date Price: €26.8 (-4.96%)

Transcript 10-Q8-K

Operator

Good day, and thank you for standing by. Welcome to Revolution Medicines' Second Quarter 2023 Earnings Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Erin Graves, Senior Director of Corporate Communications and Investor Relations. Please go ahead.

Erin Graves

Revolution Medicines, Inc. - Senior Director of Corporate Communications & IR

Thank you, and welcome, everyone, to the Second Quarter 2023 Earnings Call. Joining me on today's call are Dr. Mark Goldsmith, Revolution Medicines' Chairman and Chief Executive Officer; and Jack Anders, our Chief Financial Officer. Dr. Steve Kelsey, our President of R&D, will join us for the Q&A portion of today's call.

As we begin, I would like to note that our presentation will include statements regarding the current beliefs of Revolution Medicines with respect to our business and the proposed acquisition of EQRx, including statements regarding our development plans and time lines

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.